Schizoaffective Disorder: Symptoms, Diagnosis, and Treatment
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Schizoaffective disorder is a psychiatric diagnosis used when a person experiences both schizophrenia-spectrum psychotic symptoms and substantial episodes of depression or mania in a pattern defined by a diagnostic classification. Hallucinations, delusions, disorganized thinking, and changes in functioning may coexist with major mood episodes. The defining clinical question is how psychosis and mood episodes unfold together and separately over time. The diagnosis guides assessment and treatment, but it cannot be established from one symptom, a questionnaire, or a single difficult day. MedlinePlus Genetics provides an overview of its clinical features and the uncertainty surrounding its boundaries.
The disorder often requires coordinated care for psychotic symptoms, mood episodes, physical health, everyday functioning, and the person’s own goals. Some people have long periods of stability and substantial recovery, while others need ongoing support. The available evidence favors individualized, collaborative treatment rather than a predetermined prognosis. This guide explains symptoms, DSM-5-TR and ICD-11 diagnosis, differential assessment, treatment options, risk and safety, and practical routes to care.
What Is Schizoaffective Disorder?
Schizoaffective disorder belongs to the group of schizophrenia spectrum and other primary psychotic disorders in the DSM diagnostic framework. Its name combines schizophrenia-spectrum psychotic phenomena with affective, or mood, episodes. Psychosis is a clinical syndrome: a cluster of experiences involving changes in perception, belief formation, thinking, and sometimes behavior or organization. Affective episodes refer to syndromes such as major depression or mania; ordinary sadness, irritability, or a brief mood swing do not meet that threshold.
The diagnosis does not mean that someone has two complete, independently established disorders simultaneously. It describes a specific relationship among symptom syndromes across a person's illness. The key clinical challenge is differentiating this longitudinal pattern from schizophrenia accompanied by some depressive symptoms and from bipolar or depressive disorders in which psychosis happens during mood episodes. Tandon and colleagues' DSM-5 review explains why mood-psychosis timing and duration matter.
Schizoaffective disorder versus psychosis
A hallucination is a perception-like experience without the corresponding external stimulus; a delusion is a strongly held belief judged in context to reflect a disturbance in reality appraisal. Neither experience proves schizoaffective disorder. Psychosis can occur in schizophrenia, mood disorders, delirium, some neurological and medical illnesses, and after particular drugs or medications. Hearing a voice, for example, requires assessment of circumstances, distress, insight, sleep, medical history, and associated symptoms. For the wider syndrome, consult the NIMH guide to understanding psychosis.
What Are the Symptoms?
Psychotic symptoms
Psychotic experiences may include hearing voices or other hallucinations, persecutory or grandiose delusions, ideas of reference, disorganized speech, and markedly disorganized behavior. A person may struggle to organize a conversation, follow daily routines, or evaluate an unusual belief. Symptoms vary substantially. A person may experience only some of these phenomena, and the content of psychotic experiences alone cannot establish a specific diagnosis.
A related group of difficulties is often called negative symptoms: reductions in motivation, emotional expression, spontaneous speech, social engagement, or capacity to experience pleasure. Cognitive changes may affect attention, working memory, planning, or processing speed. Some apparent negative symptoms can also arise from depression, medication effects, anxiety, reduced opportunity, or physical illness. Clinicians must identify the cause rather than counting every difficulty as a primary psychotic symptom. The NIMH schizophrenia resource distinguishes psychotic, negative, and cognitive symptom domains.
Depressive episodes
Major depressive episodes involve sustained changes such as depressed mood, loss of interest, sleep or appetite changes, impaired concentration, fatigue, psychomotor changes, guilt, hopelessness, and sometimes thoughts of death or suicide. Diagnosis requires the complete clinical syndrome and its duration and impact, not sadness alone. In the DSM-5-TR depressive type of schizoaffective disorder, major depressive episodes occur without a history of qualifying manic episodes. A depressive episode used for the schizoaffective diagnosis must include depressed mood, an important distinction from loss of interest alone.
Manic episodes
Mania involves a distinct, sustained period of abnormally elevated, expansive, or irritable mood together with increased energy or goal-directed activity. Associated changes can include a markedly decreased need for sleep, pressured speech, racing thoughts, unusually high confidence, distractibility, increased activity, and consequential impulsive decisions. Mania can be severe enough to require hospitalization. The DSM-5-TR bipolar type of schizoaffective disorder includes a manic episode and may also include major depressive episodes. Hypomania by itself is insufficient to establish the bipolar type.
Functioning, insight, and accompanying difficulties
Some people have trouble attending classes, maintaining employment, managing finances, caring for themselves, or sustaining relationships during episodes. Others retain many of these capacities, particularly during stable periods. Insight can vary by symptom and over time; a person may recognize some experiences as symptoms while being fully convinced of others. Anxiety, disrupted sleep, substance use, and physical-health needs frequently deserve attention, but none can be assumed from the diagnostic label.
Bipolar Type and Depressive Type
DSM-5-TR specifies bipolar type when mania forms part of the illness and depressive type when there have been major depressive episodes without mania. These labels describe the mood-presentation pattern rather than measuring severity, ability, or prognosis. The choice matters because prevention and treatment of mania differ from treatment of depression. A history of mania is especially important before choosing antidepressant therapy.
The words 'bipolar type' must not be read as a synonym for bipolar I disorder with psychotic features. Their diagnostic distinction depends on the timing of psychosis relative to full mood episodes and, under DSM, how much of the active and residual illness is occupied by major mood episodes. A clear prospective symptom timeline may be more valuable than a label assigned during an emergency evaluation.
How Is Schizoaffective Disorder Diagnosed?
DSM-5-TR: the longitudinal pattern
Under the DSM-5-TR approach, clinicians assess an uninterrupted period of illness during which a major depressive or manic episode occurs alongside the active-phase schizophrenia symptom pattern. They also establish whether hallucinations or delusions were present for at least two weeks without a major mood episode at some point during the illness. Finally, episodes meeting full criteria for major depression or mania must occupy the majority of the total active and residual portions of the illness. Effects of substances, medications, or another medical condition must be excluded as the primary explanation. This is a longitudinal clinical formulation, not a two-week home observation test. Tandon et al. discuss these criteria and their rationale.
The 'majority' rule is often misunderstood. It asks about the proportion of the relevant illness course occupied by complete major mood episodes, including active and residual phases. It does not mean that someone feels sad or euphoric for most days. Similarly, the separate two-week psychosis requirement involves delusions or hallucinations in the absence of a major mood episode, rather than the absence of any emotion. Early in illness, reliable retrospective information may be limited, so the working diagnosis can appropriately change as longitudinal evidence accumulates.
ICD-11: an episode-centered approach
ICD-11 uses an importantly different construction. The diagnostic requirements of schizophrenia and a moderate or severe depressive, manic, or mixed episode must be met in the same illness episode, with the psychotic and mood symptoms beginning together or within days of each other and both persisting for approximately one month. ICD-11 does not import the DSM requirement that major mood episodes occupy the majority of the lifetime active and residual course or the DSM requirement of a separate two-week psychosis interval. The WHO ICD-11 Clinical Descriptions and Diagnostic Requirements and the peer-reviewed First et al. comparison describe this distinction.
Consequently, the same clinical history may be classified differently under ICD-11 and DSM-5-TR. That is a difference between classification systems, not automatic evidence that one clinician ignored symptoms. For American readers, DSM language is commonly used in psychiatric assessment while ICD coding is central to health systems. Clinicians should identify the framework, describe the actual course, and revisit the formulation when new information becomes available.
What happens at an assessment?
A qualified clinician takes a detailed history of psychosis, depression, mania, sleep, medication exposure, substance use, medical illness, trauma, family history, functioning, and previous treatment. A mental-status examination explores thought, perception, mood, speech, behavior, cognition, safety, and current capacity to participate in decisions. With permission when possible, collateral information from relatives, prior clinicians, records, or school and employment histories can clarify the timeline. The assessment may span several appointments and may require urgent medical evaluation when symptoms are new or rapidly changing.
Blood tests, toxicology, neurological examination, electrocardiography, imaging, or other investigations are selected according to the presentation and differential diagnosis. They may identify treatable contributors or guide medication safety; they do not constitute a laboratory test that positively establishes schizoaffective disorder. A clinician should also assess suicide risk, self-neglect, possible coercion or abuse, catatonia, and ability to meet immediate needs. NICE CG178 describes comprehensive psychosis assessment and coordinated management.
Why can the diagnosis change?
Psychosis and mood syndromes often unfold in stages. A person may initially present with severe depression and hallucinations, later develop psychosis outside a mood episode, or eventually reveal a sustained mania history. A systematic review of 49 studies found that schizoaffective disorder had lower test-retest diagnostic reliability than schizophrenia, bipolar disorder, and unipolar depression; its average kappa was about 0.50. Santelmann and colleagues' meta-analysis supports a thoughtful approach to diagnostic uncertainty.
A separate systematic review of diagnostic shifts found that diagnoses were often revised over follow-up. These findings describe populations and older diagnostic practices; they cannot predict whether one individual's diagnosis will change. A revised diagnosis can reflect a more complete illness history rather than an earlier assessment having been careless. Treatment needs and personal recovery goals should continue to guide care throughout reassessment.
Schizoaffective Disorder Versus Related Conditions
Schizophrenia with mood symptoms
People with schizophrenia can also experience major depression, manic-like symptoms, and distress. Under DSM-5-TR, schizoaffective disorder requires that full mood episodes occupy the majority of the active and residual illness course. If full mood episodes occur for only a minority of that course while the schizophrenia criteria are otherwise met, schizophrenia may be a better fit. A clinician should consider medication effects, grief, negative symptoms, and depressive syndromes separately. The full spectrum overview is covered by our schizophrenia guide.
Bipolar disorder with psychotic features
In bipolar disorder with psychotic features, psychosis occurs in the context of mood episodes; its timing and the full longitudinal history are pivotal. Schizoaffective disorder under DSM additionally requires a sufficiently long period of psychosis outside a full major mood episode. It is easy to confuse the conditions when a clinician sees only one hospitalization, especially a manic episode with strong grandiose or persecutory beliefs. The English Hub's separate comparison Bipolar Disorder vs Schizophrenia and Schizoaffective Disorder addresses that particular mood-disorder comparison.
Major depressive disorder with psychotic features
Psychotic depression refers to a major depressive episode accompanied by psychotic symptoms. Under DSM rules, psychotic symptoms are confined to the major depressive episode; schizoaffective disorder requires psychosis outside such episodes plus its majority-of-course mood criterion. Severe depression without psychosis is different again. Medication selection and safety follow the established condition-specific evidence; a label should never be inferred solely from the content of a delusion.
Other primary and secondary psychotic conditions
Schizophreniform disorder resembles schizophrenia but is defined by a shorter overall duration under DSM, and brief psychotic disorder involves a shorter episode with additional course requirements. Delusional disorder has a different symptom pattern and functional profile. Substance- or medication-induced psychosis requires a plausible exposure relationship; acute delirium typically involves fluctuating attention and awareness and is a medical concern. Neurological disorders, autoimmune or infectious diseases, endocrine disturbances, seizures, and neurocognitive disorders may also produce psychotic symptoms. These differentials are particularly important when onset is sudden, unusual, or accompanied by fever, confusion, focal neurological findings, intoxication, withdrawal, or changes in consciousness.
How do clinicians distinguish these disorders in practice?
Clinicians reconstruct dated episodes: when the first hallucinations or delusions began, whether the person met full major-depression or mania criteria at those times, how long psychosis continued after mood symptoms resolved, what happened between episodes, and what substances or medical events were present. They evaluate functioning and the quality of the evidence, not only totals on a symptom checklist. A second opinion or specialist psychosis service can be helpful when substantial uncertainty remains.
Causes and Risk Factors
The exact causes of schizoaffective disorder remain incompletely understood. Research points toward multiple contributing factors rather than one cause. Genetic influences overlap with schizophrenia, bipolar disorder, and depression. Family history can increase risk but does not determine an individual's outcome. The NIH MedlinePlus Genetics review describes the complexity of heritability and the difficulty of separating the disorder genetically from neighboring diagnoses.
Brain development, neurotransmitter signaling, sleep-circadian processes, and environmental stressors have been studied across psychosis and mood disorders, but findings for schizophrenia or bipolar disorder should not automatically be represented as proved causes of schizoaffective disorder. Substance exposure, particularly in a person with psychotic vulnerability, may influence symptom onset or recurrence; association alone does not establish that an exposure caused a specific illness. Research has yet to produce a validated biomarker that diagnoses schizoaffective disorder in an individual.
How Is Schizoaffective Disorder Treated?
Treatment usually combines management of psychosis and mood episodes with psychotherapy, family and social support, rehabilitation, and physical-health care. The sequence depends on current severity, the type of mood episode, previous response, side-effect burden, and the person's preferences. Much of the broad psychosocial evidence comes from studies of schizophrenia-spectrum or first-episode psychosis populations rather than schizoaffective-only trials. It should be applied thoughtfully and described with that limitation. NICE CG178 and the APA schizophrenia guideline supply a major evidence foundation for spectrum care.
Antipsychotic medication
Antipsychotic medicines can reduce hallucinations, delusions, agitation, and disorganized thinking. The choice is a clinical decision weighing past effectiveness, other medical problems, side effects, adherence preferences, interaction risks, and pregnancy-related considerations where relevant. Paliperidone has US labeling specifically addressing schizoaffective disorder; the DailyMed oral paliperidone prescribing information describes evidence for adult acute treatment alone or as an adjunct to a mood stabilizer or antidepressant. Other antipsychotics are also used clinically depending on individual circumstances and regulatory status.
Long-acting injectable antipsychotics can be considered when a person prefers injections, finds daily dosing difficult, or has repeated relapse related to missed medication. In a randomized-withdrawal study, once-monthly paliperidone palmitate delayed relapse among selected adults with schizoaffective disorder who had first been stabilized on the drug. The trial by Fu and colleagues supports this use but does not prove that any one medication is best for every patient or that discontinuation outcomes in a trial match every person's experience. The DailyMed injectable paliperidone label details the indication and precautions.
Treating mania and depression
When mania is prominent, clinicians may consider a mood stabilizer such as lithium or another evidence-based bipolar-treatment strategy alongside appropriate antipsychotic care. When major depression is prominent, targeted treatment may include psychotherapy and, in selected cases, an antidepressant. Antidepressants require attention to past mania, possible mood switching, interactions, and clinical monitoring. Decisions about lithium, valproate, lamotrigine, or other medicines are not interchangeable; indications, required monitoring, reproductive safety, and evidence vary. A person should never start, combine, or abruptly stop these medications from an article.
Monitoring medication safety
Antipsychotic monitoring includes weight and waist measurements, blood pressure, glucose or HbA1c, lipid levels, movement effects, and other examinations or tests relevant to the chosen drug. Adverse effects can include sedation, akathisia, stiffness or tremor, tardive dyskinesia, metabolic changes, raised prolactin, sexual adverse effects, and cardiac electrical changes with some agents. Baseline assessments and ongoing review should reflect individual risk. The NICE recommendations on antipsychotic choice and monitoring emphasize shared decisions, metabolic evaluation, movement assessment, and medication review.
If substantial symptoms persist despite treatment, the first step is a careful review of the diagnosis, adherence, adequate medication trials, comorbidity, drug interactions, substance exposure, psychosocial needs, and treatment access. Clozapine may be considered by specialists for qualifying treatment-resistant psychosis presentations, particularly when schizophrenia-related indications are met. Its use requires intensive safety evaluation and monitoring, and schizoaffective-specific evidence and approval may differ from schizophrenia guidance. Catatonia or severe mood episodes may require their own specialist treatment pathways. Every escalation should be individualized.
Psychotherapy and cognitive behavioral therapy for psychosis
Psychotherapy can help people manage distressing voices or beliefs, understand triggers, address depression or anxiety, plan for relapse, and pursue meaningful goals. Cognitive behavioral therapy for psychosis (CBTp) works collaboratively on interpretations of experiences, coping, and functioning; it is not a test of whether a person is telling the truth. Evidence-based psychosis guidelines recommend CBT and family interventions in combination with medical and social care. Outcomes vary, and trials of CBTp generally include broader psychosis populations rather than exclusively schizoaffective disorder. NICE CG178 specifies structured delivery of these interventions.
Family psychoeducation, cognitive support, and rehabilitation
Family psychoeducation can support communication, shared planning, recognition of relapse signs, and practical problem-solving, with participation guided by the person's consent and preferences. Cognitive remediation uses structured exercises and strategy training to address cognitive difficulties, often integrated with real-world support. Supported education and employment, housing assistance, peer support, and case management help translate symptom improvement into daily participation. The NIMH overview of evidence-based schizophrenia treatments and NICE recovery recommendations support this broader model.
Early intervention and coordinated specialty care
For a first episode of psychosis, early referral matters even when the final diagnosis remains uncertain. Coordinated specialty care integrates psychiatric treatment, psychotherapy, family education, supported work or education, and case management around the person's goals. The evidence base comes chiefly from first-episode psychosis programs rather than schizoaffective-only populations, but the pathway is relevant before diagnostic certainty is possible. NIMH's Understanding Psychosis details coordinated specialty care and the importance of timely access.
What Does Recovery Look Like?
Recovery can include fewer and less distressing psychotic experiences, stable mood, meaningful relationships, education or employment, housing security, physical health, and more control over decisions. Some people achieve long symptom-free intervals; others manage fluctuating symptoms while remaining involved in valued activities. Treatment outcomes depend on factors such as the pattern of illness, access to care, co-occurring conditions, response to medications, and social circumstances. Group studies of diagnostic stability or relapse should never be used as a prediction for a particular person.
A recovery plan may document preferred supports, personal warning signs, strategies that have helped, emergency contacts, and what clinicians should know if decision-making becomes difficult during an episode. It can also address treatment side effects, costs, transportation, housing, and discrimination. The person experiencing the disorder should play a central role in these decisions, with reasonable accommodations and trusted family involvement when welcomed. NIMH emphasizes recovery-oriented, shared planning.
Relapse Prevention and Everyday Management
Recurrence can involve either psychotic symptoms, significant mood symptoms, or both. An individualized plan looks for changes from the person's usual pattern, such as progressive sleep disruption, renewed suspiciousness, worsening voices, loss of daily structure, new hopelessness, unusually high energy, or missed treatments. These signs are prompts for review, not proof that a full relapse is happening. The response may include contacting the care team, checking medication adverse effects or adherence, evaluating physical health, and adjusting social supports.
Regular sleep, manageable activity, follow-up visits, attention to medical conditions, and avoiding intoxicants associated with past deterioration may support stability, but lifestyle practices cannot replace treatment for a clinical psychotic or mood episode. Decisions about a gradual medication change belong with the treating clinician. When a medication causes distressing effects, the appropriate goal is to change the treatment plan collaboratively, preserving both safety and quality of life.
When Is Urgent Medical or Mental Health Care Needed?
A first episode of rapidly developing psychosis deserves prompt professional assessment, particularly with confusion, altered consciousness, fever, seizures, head injury, new neurological symptoms, intoxication or withdrawal, or a major medication change. These signs can indicate a time-sensitive medical cause. Immediate emergency evaluation is also appropriate for suicidal intent, an inability to eat or drink or maintain basic safety, severe agitation with imminent danger, or suspected catatonia such as prolonged immobility, mutism, rigidity, or marked unresponsiveness. Call local emergency services when there is immediate danger.
If someone is expressing suicidal thoughts, ask directly and calmly about immediate safety, stay with them if it is safe to do so, remove access to imminent means where possible without escalating risk, and seek urgent professional help. For readers in the United States, calling or texting 988 reaches the Suicide & Crisis Lifeline; elsewhere use local crisis and emergency services. Supportive communication avoids arguments over a delusion's content while acknowledging the fear or distress the person is experiencing. This section describes routes to care, not a substitute for emergency assessment.
How to Support Someone With Schizoaffective Disorder
Start with the specific concern you have noticed and ask what kind of support would be welcome. Use calm, concrete language: 'You seem frightened and haven't slept; would you like me to help arrange an appointment?' Listen without ridicule and avoid confirming a frightening belief as fact. Offer transportation, help organizing records or appointments, assistance with groceries or routine tasks, and a way to contact the treatment team with permission. During mania, decisions involving money, driving, or significant risk may call for prompt clinical attention.
Caregivers can also need education, respite, and support of their own. Respect for privacy, autonomy, and culturally appropriate care matters even during periods of severe symptoms. When immediate safety is in question, prioritize professional emergency assessment. At other times, a collaboratively prepared crisis and relapse plan can reduce confusion about what the person wants and who is authorized to assist.
Common Questions About Schizoaffective Disorder
Is schizoaffective disorder the same as schizophrenia?
They are separate diagnostic categories with overlapping psychotic symptoms. In DSM-5-TR, schizoaffective disorder also requires full major mood episodes occupying most of the active and residual illness, plus a period of delusions or hallucinations outside a full mood episode. Schizophrenia can include mood symptoms, but the longitudinal distribution differs.
Can someone have schizoaffective disorder without hallucinations?
Hallucinations are one possible psychotic symptom, not a requirement that everyone must experience. DSM diagnostic evaluation examines the broader schizophrenia symptom pattern and requires a qualifying interval of hallucinations or delusions outside a major mood episode. Delusions may fulfill that component even when the person has never heard voices.
What is the difference between the bipolar and depressive types?
Bipolar type involves a history of a qualifying manic episode, with or without major depressive episodes; depressive type involves major depressive episodes and no mania. Treatment plans account for these different mood risks alongside psychosis.
Does schizoaffective disorder always last for life?
The course varies, and there is no basis for predicting an individual lifetime trajectory from the name of the disorder. Some people experience substantial or prolonged remission and good functioning, while others require continuing coordinated care. Treatment planning should respond to current needs and changes over time.
Can schizoaffective disorder be cured?
Clinicians generally focus on remission, relapse prevention, functioning, safety, and quality of life rather than promising a permanent cure. Effective treatment and support can make a major difference, and meaningful recovery is possible even when continued management is needed.
Can a blood test, MRI, or online quiz diagnose it?
No. Tests may help evaluate other causes or treatment safety; questionnaires can flag concerns but do not establish the longitudinal relationship required for diagnosis. A comprehensive professional evaluation is essential.
Can a person with schizoaffective disorder work or study?
Yes. Individual abilities, supports, accommodations, symptoms, and treatment response vary. Supported employment or education programs can help people stay engaged or return after an episode. The diagnosis alone should not be treated as a measure of capability.
Is schizoaffective disorder caused by trauma or cannabis?
No single established cause explains all cases. Genetic and environmental contributors are under investigation. Trauma and substance exposure can be clinically relevant, but their presence does not prove a particular diagnosis or establish a unique causal explanation. Medical and substance-related psychosis must be considered during assessment.
What if two doctors give different diagnoses?
Ask each clinician to explain which diagnostic framework they used, the dated pattern of mood and psychotic episodes, and which facts remain uncertain. Reviewing prior records and following symptoms over time may resolve the difference. A specialist second opinion can help when treatment or practical decisions depend on the distinction.
What should someone do after a first psychotic episode?
Arrange prompt assessment by an experienced mental-health or early-psychosis service, and seek emergency medical attention if confusion, physical warning signs, suicidal intent, or impaired safety are present. Early treatment can begin while the precise diagnosis is still being clarified.
The Clinical Takeaway
Schizoaffective disorder is diagnosed through the relationship of full mood episodes and schizophrenia-spectrum psychosis, assessed over an appropriate time frame and interpreted within a specified classification. Its symptoms require a thorough differential, and treatment usually integrates antipsychotic care, appropriate mood management, psychotherapy, family and social supports, safety monitoring, and a person-centered recovery plan. A useful diagnosis makes treatment more precise while leaving room for reassessment and the person's own goals.
Related Articles
Schizophrenia: Symptoms, Causes, Diagnosis, Treatment, and Recovery — overview of schizophrenia symptoms, clinical assessment, treatment, and recovery.
Bipolar Disorder vs Schizophrenia and Schizoaffective Disorder — how mood episodes, psychosis, and longitudinal patterns differentiate these diagnoses.
References
American Psychiatric Association. (2020). The APA Practice Guideline for the Treatment of Patients With Schizophrenia. Official guideline.
DailyMed, National Library of Medicine. (2025). INVEGA SUSTENNA: paliperidone palmitate extended-release injectable suspension, prescribing information. FDA labeling.
DailyMed, National Library of Medicine. (2026). Paliperidone extended-release tablets: prescribing information. FDA labeling.
First, M. B., Gaebel, W., Maj, M., et al. (2021). An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5. World Psychiatry. DOI: 10.1002/wps.20825.
Fu, D.-J., Turkoz, I., Simonson, R. B., et al. (2015). Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. Journal of Clinical Psychiatry, 76(3), 253–262. DOI: 10.4088/JCP.14m09416.
MedlinePlus Genetics, National Library of Medicine. Schizoaffective disorder. NIH resource.
National Institute for Health and Care Excellence. (2014; updated recommendations). Psychosis and schizophrenia in adults: prevention and management (CG178). Clinical guideline.
National Institute of Mental Health. Schizophrenia. NIMH health publication.
National Institute of Mental Health. Understanding Psychosis. NIMH health publication.
Santelmann, H., Franklin, J., Bußhoff, J., Baethge, C. (2015). Test-retest reliability of schizoaffective disorder compared with schizophrenia, bipolar disorder, and unipolar depression: a systematic review and meta-analysis. PubMed.
Santelmann, H., Franklin, J., Bußhoff, J., Baethge, C. (2016). Diagnostic shift in patients diagnosed with schizoaffective disorder: a systematic review and meta-analysis of rediagnosis studies. Bipolar Disorders. DOI: 10.1111/bdi.12388.
Tandon, R., et al. (2013). Schizoaffective disorder in the DSM-5. Schizophrenia Research. PubMed.
World Health Organization. (2024). Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. WHO publication.